Back to results
US 2026/0140124 A1Published application
Pcos stratification
AssigneeThe University of Birmingham
InventorWiebke ARLT
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeThe University of Birmingham
InventorWiebke ARLT
Estimating the term…
The present invention provides a method of stratifying test subjects with Polycystic Ovary Syndrome (PCOS) into those that are expected to respond to therapeutic treatment with an inhibitor of hypothalamic-pituitary-adrenal axis activity, those that are expected to respond to therapeutic treatment with an AKR1C3 inhibitor, and those that are expected to respond to therapeutic treatment with a 5alpha-reductase inhibitor, the method comprising: (a) providing a test sample from a test subject with PCOS; (b) determining the concentration/level in the test sample of at least one ovarian androgen steroid and/or a derivative thereof, and at least one adrenal steroid and/or derivative thereof; and (c) using the results from (b) to predict if the subject will respond to therapeutic treatment with an inhibitor of hypothalamic-pituitary-adrenal axis activity, therapeutic treatment with an AKR1C3 inhibitor, or therapeutic treatment with a 5alpha-reductase inhibitor.
A method of stratifying test subjects with Polycystic Ovary Syndrome (PCOS) into those that are expected to respond to therapeutic treatment with an inhibitor of hypothalamic-pituitary-adrenal axis activity, those that are expected to respond to therapeutic treatment with an AKR1C3 inhibitor, and those that are expected to respond to therapeutic treatment with a 5alpha-reductase inhibitor, the method comprising:
The method according to any one of the preceding claims, wherein the at least one adrenal steroid may be selected from the group comprising dehydroepiandrosterone sulfate (DHEAS), dehydroepiandrosterone (DHEA), 11-hydroxyandrostenedione (11OHA4), 11-ketoandrostenedione (11KA4), 11-ketotestosterone (11KT), 11-hydroxytestosterone (11OHT), pregnenolone, 17-hdyroxypregnenolone, 17-hydroxyprogesterone (17OHP), 11-deoxycortisol (S), cortisol (F), d11-deoxycorticosterone (DOC), corticosterone (B) and aldosterone (Aldo).
A method of stratifying test subjects with PCOS into those that are expected to respond to therapeutic treatment with an inhibitor of hypothalamic-pituitary-adrenal axis activity, those that are expected to respond to therapeutic treatment with an AKR1C3 inhibitor, and those that are expected to respond to therapeutic treatment with a 5alpha-reductase inhibitor, the method comprising:
A method of stratifying test subjects with PCOS into those that are expected to respond to therapeutic treatment with an inhibitor of hypothalamic-pituitary-adrenal axis activity, those that are expected to respond to therapeutic treatment with an AKR1C3 inhibitor, and those that are expected to respond to therapeutic treatment with a 5alpha-reductase inhibitor, the method comprising:
The method according to any one of the preceding claims, wherein the method comprises comparing the concentrations/levels determined in (b) with reference concentrations of the steroids and/or their derivatives thereof from other subjects with PCOS.
Dependencies are inferred from the claim text.